-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
People's Daily Online, Beijing, July 20 (Reporter Hongli Sun) According to the official website of the State Food and Drug Administration, the State Food and Drug Administration recently issued a notice that it was inspected by 7 drug inspection institutions including Gansu Provincial Institute of Drug Inspection and labeled as Anhui Jishantang Chinese Medicine Fifteen batches of medicines including Bupleurum (North Bupleurum) produced by 14 companies including Technology Co.
According to the notice, the first batch of penciclovir cream produced by Hubei Keyi Pharmaceutical Co.
According to the inspection by Fujian Food and Drug Quality Inspection Institute, a batch of chloramphenicol eye drops produced by Guangdong Hongying Technology Co.
According to the inspection by Shandong Food and Drug Inspection and Research Institute, a batch of brain spirit capsules produced by Jiangxi Yaodu Zhangshu Pharmaceutical Co.
According to the inspection by Beijing Institute for Drug Control, a batch of Xinnaoxin tablets produced by Hubei Ji'antang Pharmaceutical Co.
After inspection by Chongqing Food and Drug Inspection and Testing Research Institute, a batch of Zhuanggu Musk analgesic ointment produced by Jiuzhaigou Natural Pharmaceutical Group Co.
According to the inspection by Hubei Institute of Drug Administration and Inspection, a batch of Atractylodes japonicus produced by Beijing Boaitang Anguo Chinese Medicine Technology Co.
The 2 batches of Bupleurum produced by Guangxi Lanzheng Pharmaceutical Co.
The State Food and Drug Administration stated that for the above-mentioned non-compliant drugs, the drug regulatory department has required relevant companies and units to take risk control measures such as suspension of sales and use, recalls, etc.